Fexinidazole_product_DataBase

Bioactivity

Fexinidazole (HOE 239) is an orally active, potent nitroimidazole antitrypanosomal drug. Fexinidazole shows trypanocidal activity against T. brucei subspecies and strains with IC50s of 0.7-3.3 μM (0.2-0.9 μg/ml). Fexinidazol has the potential for human sleeping sickness (HAT) caused by infection with T. brucei[1].

Invitro

Fexinidazole (HOE 239) has two principal metabolites, sulfoxide and sulfone. They have shown trypanocidal activity in vitro with IC50s of 0.7-3.3 μM (0.2-0.9 μg/ml) range against all parasite strains tested[1].

In Vivo

Fexinidazole (HOE 239; 20-50 mg/kg/day of IP or 25-100 mg/kg/day of PO; four consecutive days) has antitrypanosomal activities[1]. Animal Model:

Name

Fexinidazole

CAS

59729-37-2

Formula

C12H13N3O3S

Molar Mass

279.31

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Kaiser M, et al. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother. 2011 Dec;55(12):5602-8.

PeptideDB

Fexinidazole

CAS: 59729-37-2 F: C12H13N3O3S W: 279.31